Immobilized RBD of SARS-CoV-2 Spike Protein
SARS-CoV-2 is the novel coronavirus that causes CoronaVirus Disease 2019 (COVID-19). The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein binds to the cell receptor ACE2 allowing viral entry and infection. It is a 223 amino acid glycoprotein representing residues 319-541 of the spike protein S1 sequence. Immobilized RBD from Molecular Innovations is useful for capturing SARS-CoV-2 specific antibodies from human plasma and serum. Immobilized RBD of SARS-CoV-2 Spike Protein is highly specific and reusable. Recombinantly produced in HEK cell culture and purified by chelated metal affinity chromatography. Contains a 6X-Histidine tag at C terminus for purification.
Produced under license from the Icahn School of Medicine at Mount Sinai, New York, NY, USA.